A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 394 participants.

Also called NCT01468181

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 394 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01468181
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01468181. Non-randomized; no masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-12 (actual). Results posted on 2014-12-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
LY2189265
Intervention (Drug)
Sulfonylureas (SU)
Intervention (Drug)
Biguanides (BG)
Intervention (Drug)
alpha-glucosidase inhibitor (a-GI)
Intervention (Drug)
Thiazolidinedione (TZD)
Intervention (Drug)
Glinides
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01468181
Content hash
ad991b52b3780f617cd07e25585ae1713989fbd02a3498196b8f7ced81be74d0